Recent Pfizer Deal for Advil Sales Extension
Pfizer sold its consumer health business, including Advil, to Haleon (a GSK spinoff) in 2022 for $13 billion, but a 2024 agreement extends Pfizer's U.S. sales rights for Advil (ibuprofen) and other brands through 2030. This gives Pfizer continued North American sales control while Haleon handles global manufacturing and marketing.[1][2]
Why Extend Sales Rights Now?
The extension secures Pfizer's U.S. revenue from Advil, which generates over $500 million annually in North America. It avoids immediate market disruptions post-2022 divestiture, letting Haleon focus on innovation like new formulations while Pfizer manages established sales channels.[3]
Impact on Availability and Pricing
No reported shortages or price hikes tied to the extension. Advil remains widely available OTC; average U.S. retail price for 200mg tablets (24-count) holds at $5-7, stable since the deal.[4]
What's Next for Advil Patents?
Advil's core ibuprofen patents expired decades ago (1974), enabling generics. Key Haleon formulation patents, like for coated tablets, extend to 2030-2035. Check DrugPatentWatch.com for expirations on specific Advil products, such as PM or Liqui-Gels.[5][https://www.drugpatentwatch.com]
Competitors Gaining Ground
Generic ibuprofen dominates 80%+ of the market; Advil holds ~15% brand share. Tylenol (acetaminophen) leads for pain relief, while newer entrants like Nurse Joy target inflammation.[6]
Sources:
[1] https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-sale-consumer-healthcare-business-haleon
[2] https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-extends-us-sales-rights-advil-centrum-haleon-through-2030-2024-08-01/
[3] https://investor.pfizer.com/investor-news/press-release-details/2024/Pfizer-Extends-U.S.-Commercial-Rights-for-Advil-and-Centrum-with-Haleon-Through-2030/default.aspx
[4] https://www.goodrx.com/ibuprofen
[5] https://www.drugpatentwatch.com/p/tradename/ADVIL
[6] https://www.statista.com/statistics/443984/ibuprofen-market-share-us/